SNDL Inc. (SNDL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.44. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SNDL = $188.97 (+13022.9% from the current price, the stock appears undervalued). Analyst consensus target is SNDL = $4 (+174.3% upside).
Valuation: SNDL trades at a trailing Price-to-Earnings (P/E) of -30.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.62.
Financials: revenue is $946M, +10.6%/yr average growth. Net income is $16M (loss), growing at +60.7%/yr. Net profit margin is -1.7% (negative). Gross margin is 27.3% (+7.6 pp trend).
Balance sheet: total debt is $170M against $1.1B equity (Debt-to-Equity (D/E) ratio 0.15, conservative). Current ratio is 4.88 (strong liquidity). Debt-to-assets is 12.7%. Total assets: $1.3B.
Analyst outlook: 1 / 6 analysts rate SNDL as buy (17%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 37/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).
